At Vigilare Biopharma, our Regulatory Intelligence (RI) solutions enable pharmaceutical and medical technology companies to design efficient strategies for product development, registration, and market entry across diverse jurisdictions. We analyze evolving global regulations to equip sponsors and marketing authorization holders with timely, accurate, and region-specific insights needed for compliance and commercialization success.
Our tailored RI offerings support the entire product lifecycle from pre-market feasibility and strategic planning to post-market monitoring ensuring informed regulatory decisions that minimize risks and accelerate approvals.
Vigilare Biopharma’s Drug Regulatory Intelligence (DRI) services are designed to help pharmaceutical and biopharmaceutical organizations navigate complex, country-specific regulatory environments. We understand that precise and up-to-date information can determine the success of product registration and launch.
Our Drug RI specialists deliver:
Our Medical Devices Regulatory Intelligence (MDRI) services provide critical insights to help manufacturers and distributors comply with varying national and regional device regulations. We support companies throughout the device registration, certification, and post-market phases, ensuring robust compliance management aligned with local authority expectations.
Key offerings include:
Regulatory intelligence supports strategy by identifying the fastest regulatory pathways such as Breakthrough Therapy Designation, PRIME, and Orphan Drug status, benchmarking clinical trial designs against recently approved precedents in the same indication, flagging new agency expectations before a submission is filed, and monitoring competitor label negotiations to anticipate class labeling shifts. Early RI reduces the risk of designing trials that fail to meet evolving agency standards and improves the quality of pre-submission interactions with regulators.
Key regulatory intelligence sources include FDA.gov for guidance documents and PDUFA commitments, the EMA EPAR database, ICH guidelines, Drugs@FDA for approved product labels, Federal Register notices, WHO prequalification updates, Regulations.gov for proposed rulemaking, and specialized databases like Citeline Regulatory, Clarivate, and GlobalData. Leading RI consultants also monitor agency social media, public meeting transcripts, and published inspection classification data.
Yes. Outsourced regulatory intelligence services are specifically designed for small biotechs and virtual companies that cannot justify a full-time RI function. Engagement models range from on-demand horizon scanning reports starting around $2,000 to $5,000 per month to comprehensive competitive intelligence programs. Many regulatory consulting firms offer modular RI packages such as weekly regulatory digests, indication-specific competitive landscape analyses, or one-time guidance gap assessments that scale with the company stage and budget.
Market intelligence focuses on commercial factors such as sales trends, market share, pricing, and competitor positioning. Regulatory intelligence focuses on the approval environment: agency guidance, submission standards, labeling precedents, inspection trends, and policy changes. While both inform business decisions, regulatory intelligence is specifically action-oriented for regulatory affairs and R&D functions. Companies with integrated RI and market intelligence capabilities can build development and launch strategies that align scientific, regulatory, and commercial goals simultaneously.